Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

IFX 1

Drug Profile

IFX 1

Alternative Names: CaCP 29; IFX-1

Latest Information Update: 05 Aug 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Beijing Mabworks Biotech; InflaRx
  • Developer InflaRx
  • Class Anti-infectives; Anti-inflammatories; Antivirals; Monoclonal antibodies; Skin disorder therapies; Vascular disorder therapies
  • Mechanism of Action Complement C5a inhibitors; Inflammation mediator modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Pneumonia
  • Phase II Granulomatosis with polyangiitis; Hidradenitis suppurativa; Microscopic polyangiitis; Pyoderma gangrenosum; Sepsis; Systemic inflammatory response syndrome
  • Preclinical Cancer
  • No development reported Inflammation

Most Recent Events

  • 30 Jul 2020 InflaRx intends to submit biologic license application with the US FDA for Hidradenitis suppurativa
  • 30 Jul 2020 InflaRx plans a phase III trial in Hidradenitis suppurativa in USA and Europe
  • 30 Jul 2020 InflaRx plans a phase IIa trial for Cancer (Combination therapy) (IV) first half of 2021
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top